ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 186

The Accuracy and Potential Impact of a Diagnostic Decision Support System in Rare Disease Cases

Simon Ronicke1,2, Martin C. Hirsch3, Ewelina Türk3, Katharina Larionov2, Daphne Tientcheu2 and Annette D. Wagner2, 1Ada Health GmbH, Belrin, Germany, 2Nephrology, Medical School Hannover, Hannover, Germany, 3Ada Health GmbH, Berlin, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: diagnosis, differential diagnosis, digital technologies, Education, medical and educational research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Education Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Diagnosis in rare diseases cases is often delayed by several years. Main factors for delayed diagnosis are believed to be lack of awareness and knowledge about rare diseases among health care professionals. Diagnostic decision support systems (DDSS) have the potential to enhance clinical diagnosis by assessing case data based on incorporated medical knowledge and by suggesting relevant differential diagnoses. DDSS can contribute to professional support and education by visualising medical information and reasoning. We report about the use of Ada/DX, a DDSS in development, in an outpatient clinic for rare inflammatory systemic diseases. Presenting preliminary results, we evaluate the system’s diagnostic accuracy and assess the potential impact of this diagnostic and educational tool on the time to diagnosis.

Methods: This retrospective study is being conducted at the outpatient clinic for rare inflammatory systemic diseases at the Hannover Medical School, Germany. Ethical approval was obtained from the local ethics committee. To date, 82 (of a total 120) patient cases with confirmed diagnosis were included. The time of the visit of first documented symptoms and the time of diagnosis were identified. Time to diagnosis (TD) was calculated. Documented clinical evidence from the medical record was transferred to the DDSS and the disease suggestions in the DDSS were evaluated. Primary endpoint was the correctness of top disease suggestions for the visit of diagnosis. In these cases, secondary endpoints were the time to first correct top rare disease suggestion (T1R) and the time to first correct top 5 rare disease suggestion (T5R). The difference between TD and T1R and the difference between TD and T5R was calculated. Wilcoxon signed-rank test was conducted.

Results: On preliminary evaluation, primary accuracy of top suggestions of the DDSS at the time of diagnosis was 80.5% (71.9% to 89.1%, 95% CI). The table shows a comparison of the original time to diagnosis without the use of the DDSS and the time to correct disease suggestions with the use of the DDSS. (All times are expressed in months.)

Mean Std Dev PCTL 25 PCTL 50 PCTL 75
Among all cases
Time to diagnosis (TD) in medical record 57.8 84.2 2.3 18.0 74.5
Among cases with correct top suggestion at time of diagnosis
Time to correct top rare disease suggestion (T1R) 25.0 50.6 0.0 3.0 21.0
Time to correct top 5 rare disease suggestion (T5R) 13.1 31.9 0.0 0.0 5.3
Time difference (TD – T1R) 29.6 70.5 0.0 1.0 19.3
Time difference (TD – T5R) 41.5 78.3 0.8 9.5 40.0

The Wilcoxon signed-rank test shows a significant difference for TD – T1R (z-score -5.37, α=0.05, p<0.001) and TD – T5R (z-score -6.03, α=0.05, p<0.001). Main reasons for incorrect DDSS disease suggestions were multi-morbidity (cases with multiple relevant diagnoses), atypical disease presentation and high level of case complexity.

Conclusion: The DDSS suggested the correct diseases based on information from the medical record in most of the analysed rare disease cases. The DDSS often suggested the correct diseases at times prior to the visit of diagnosis. DDSS could be used as educational tools that suggest relevant differential diagnoses in rare disease cases. They might help to reduce time to diagnosis and improve patient outcomes. Prospective research is needed to verify the results.


Disclosure: S. Ronicke, Ada Health GmbH, 3; M. C. Hirsch, Ada Health GmbH, 4; E. Türk, Ada Health GmbH, 3; K. Larionov, None; D. Tientcheu, None; A. D. Wagner, None.

To cite this abstract in AMA style:

Ronicke S, Hirsch MC, Türk E, Larionov K, Tientcheu D, Wagner AD. The Accuracy and Potential Impact of a Diagnostic Decision Support System in Rare Disease Cases [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-accuracy-and-potential-impact-of-a-diagnostic-decision-support-system-in-rare-disease-cases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-accuracy-and-potential-impact-of-a-diagnostic-decision-support-system-in-rare-disease-cases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology